Vector Labs Ab02241-14.0 Anti-RSV F protein [MEDI-493 (Palivizumab, hu129)], Human IgE, kappa (50 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: MEDI-493 (Palivizumab, hu129)
Synonyms: F2; Fusion glycoprotein F0; Protein F; F gycoprotein; Human respiratory syncytial virus; humanized mAb 129
Amount: 50 μg
Application Codes Clone: Therapeutic; NTRL; ELISA; WB
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG1
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement: This antibody recognizes the site A of the RSV F glycoprotein. This antibody binds the 'NSELLSLINDMPITNDQKKLMSNN' epitope (PMID: 20098425).
Application Notes: This broadly neutralizing antibody is recommended to be used as a prophylactic agent for infants with risk for RSV infections. The binding and functional properties of this antibody were studied using ELISA and in vitro neutralization assays. The affinity of MEDI-493 was found to be 1.4 nM, equal to or slightly better than an isotype matched chimeric derivative of mAb 1129 (Johnson et al., 1997). Pretreatment of cotton rats with MEDI-493 resulted in 99% reduction of lung RSV titers at a dose of 2.5 mg/kg, corresponding to a serum concentration of 25-30 microg/mL (PMID: 9359721). MEDI-493 was safe and well-tolerated in this high risk pediatric population (PMID: 9493805). It was reported that monthly intramuscular doses of 15 mg/kg maintained mean trough serum concentrations that were above 40 microg/ml (the value associated with 99% reduction of pulmonary RSV in the cotton rat model) (PMID: 9779762). Phase III clinical trial showed that MEDI493 significantly reduced hospitalizations due to RSV infection. A comparative study indicated that MEDI-493 was consistently 4- to 5-fold more potent than RSHZ19 in antigen binding, RSV neutralization, and fusion inhibition assays (PMID: 10353858). MEDI-493 was used to study the resistant escape mutants and the reactivity of their F protein was tested using western blotting (PMID: 14972528). It is reported that ultraviolet (UV) light irradiation of MEDI-493 causes the loss of binding and biological activity which is attributed to a single tryptophan residue (PMID: 17319649). This antibody is commercially available as SYNAGIS®.

Product Class:	Purified
Clone ID:	MEDI-493 (Palivizumab, hu129)
Synonyms:	F2; Fusion glycoprotein F0; Protein F; F gycoprotein; Human respiratory syncytial virus; humanized mAb 129
Amount:	50 μg
Application Codes Clone:	Therapeutic; NTRL; ELISA; WB
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG1
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement:	This antibody recognizes the site A of the RSV F glycoprotein. This antibody binds the 'NSELLSLINDMPITNDQKKLMSNN' epitope (PMID: 20098425).
Application Notes:	This broadly neutralizing antibody is recommended to be used as a prophylactic agent for infants with risk for RSV infections. The binding and functional properties of this antibody were studied using ELISA and in vitro neutralization assays. The affinity of MEDI-493 was found to be 1.4 nM, equal to or slightly better than an isotype matched chimeric derivative of mAb 1129 (Johnson et al., 1997). Pretreatment of cotton rats with MEDI-493 resulted in 99% reduction of lung RSV titers at a dose of 2.5 mg/kg, corresponding to a serum concentration of 25-30 microg/mL (PMID: 9359721). MEDI-493 was safe and well-tolerated in this high risk pediatric population (PMID: 9493805). It was reported that monthly intramuscular doses of 15 mg/kg maintained mean trough serum concentrations that were above 40 microg/ml (the value associated with 99% reduction of pulmonary RSV in the cotton rat model) (PMID: 9779762). Phase III clinical trial showed that MEDI493 significantly reduced hospitalizations due to RSV infection. A comparative study indicated that MEDI-493 was consistently 4- to 5-fold more potent than RSHZ19 in antigen binding, RSV neutralization, and fusion inhibition assays (PMID: 10353858). MEDI-493 was used to study the resistant escape mutants and the reactivity of their F protein was tested using western blotting (PMID: 14972528). It is reported that ultraviolet (UV) light irradiation of MEDI-493 causes the loss of binding and biological activity which is attributed to a single tryptophan residue (PMID: 17319649). This antibody is commercially available as SYNAGIS®.

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews